| March 2020 |
| 09 Mar |
Meeting conducted with Institutional Investors / Analysts. |
 |
| 09 Mar |
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review |
|
| 06 Mar |
Meeting conducted with Institutional Investors / Analysts. |
|
| February 2020 |
| 27 Feb |
Biocon's Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection |
|
| 26 Feb |
Meeting conducted with Institutional Investors / Analysts |
|
| 22 Feb |
Company Statement: Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection |
|
| 19 Feb |
Meetings conducted with Institutional Investors / Analysts |
|
| 18 Feb |
Meetings conducted with Institutional Investors / Analysts |
|
| 12 Feb |
Meeting conducted with Institutional Investors / Analysts |
|
| 10 Feb |
Investor Presentation |
|
| 07 Feb |
Amalgamation of Biocon Research Limited ("BRL") with Biocon Biologics India Limited ("BBIL") |
|
| January 2020 |
| 30 Jan |
Meeting conducted with Institutional Investors / Analysts |
|
| 27 Jan |
Company statement: Biocon's API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection |
|
| 23 Jan |
Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for Disclosures |
|
| 23 Jan |
Change in Directorate |
|
| 23 Jan |
Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6% |
|
| 23 Jan |
Outcome of the Board Meeting |
|
| 21 Jan |
Allotment of shares by BBIL to Activ Pine LLP |
|
| 20 Jan |
Biocon's Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA lnspection with Zero Observations |
|
| 09 Jan |
Execution of SHA and SSA with True North - Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015 |
|
| 06 Jan |
Notice of Board Meeting- Newspaper Advertisement |
|
| 06 Jan |
Press Release |
|
| 06 Jan |
True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake |
|
| 03 Jan |
Intimation of Board Meeting and Trading Window Closure |
|
